Loading...
•
Dec 31, 2024
BioCryst Q4 2024 Earnings Report
BioCryst reported strong revenue growth and reduced losses in Q4 2024.
Key Takeaways
BioCryst Pharmaceuticals posted total revenue of $131.5 million in Q4 2024, a 40.8% increase year-over-year. ORLADEYO sales grew 36.6% to $124.2 million. The company's GAAP net loss improved to $26.8 million from $61.7 million in the prior year quarter. Non-GAAP operating profit reached $16.8 million, compared to a loss of $26.2 million in Q4 2023.
Total revenue rose 40.8% year-over-year to $131.5 million.
ORLADEYO net revenue grew 36.6% to $124.2 million.
GAAP net loss narrowed to $26.8 million from $61.7 million.
Non-GAAP operating profit of $16.8 million versus a $26.2 million loss last year.
Revenue by Geographic Location
Forward Guidance
BioCryst raised its FY 2025 ORLADEYO revenue guidance to $535-$550 million, up from the previous range of $515-$535 million. The company expects positive EPS and cash flow in the second half of 2025.
Positive Outlook
- ORLADEYO revenue guidance raised to $535-$550 million.
- Total revenue projected between $560-$575 million for FY 2025.
- Sustained revenue growth expected to outpace expenses.
- Non-GAAP operating expenses forecasted at $425-$435 million.
- Targeting positive EPS and cash flow in 2H 2025.
Challenges Ahead
- Operating expenses expected to rise due to cost of goods sold and distribution costs.
- Higher incentive compensation may impact short-term profitability.
- Net losses remain despite improvement in profitability metrics.
- Continued investment in pipeline programs may limit near-term cash flow improvements.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...